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The evolution of human immunodeficiency virus type 1 (HIV-1) strains with reduced susceptibility to
protease inhibitors (PIs) is a major cause of PI treatment failure. A subset of subjects failing a therapy regimen
containing the PI nelfinavir developed mutations at position 88 in the protease region. The N88S mutation
occurring in some of these subjects induces amprenavir hypersusceptibility and a reduction of fitness and
replication capacity. Here we demonstrate that substitutions L63P and V77I in protease, in combination,
partially compensate for the loss of fitness, loss of replication capacity, loss of specific infectivity, and aberrant
Gag processing induced by the N88S mutation. In addition, these mutations partially ablate amprenavir
hypersusceptibility. Addition of mutation M46L to a strain harboring mutations L63P, V77I, and N88S
resulted in a reduction of fitness and infectivity without changing Gag-processing efficiency, while amprenavir
hypersusceptibility was further diminished. The ratio of reverse transcriptase activity to p24 protein was
reduced in this strain compared to that in the other variants, suggesting that the M46L effect on fitness
occurred through a mechanism different from a Gag-processing defect. We utilized these mutant strains to
undertake a systematic comparison of indirect, single, cycle-based measures of fitness with direct, replication-
based fitness assays and demonstrated that both yield consistent results. However, we observed that the
magnitude of the fitness loss for one of the mutants varied depending on the assay used.
The rapid, error-prone replication of human immunodefi-
ciency virus (HIV) allows viral populations in the host to adapt
quickly to changing selective pressures. One example of this
adaptability is the failure of antiretroviral therapy due to the
emergence of virus populations with reduced drug susceptibil-
ity caused by well-defined mutations in the protease region.
The majority of such resistance-associated mutations are rarely
observed in the absence of drug selection and have therefore
been hypothesized to be of lesser fitness than the predominant,
drug-susceptible virus strains (15, 16, 35). Indeed, it has been
possible to demonstrate an impairment of the catalytic effi-
ciency and polyprotein precursor processing of protease (PR)-
bearing resistance-associated mutations, as well as reduced
replicative capacity, fitness, and infectivity of resistant virus
strains (1, 3, 5, 11, 13, 18, 20–22, 26, 32, 34, 39).
Mutations at position 88 of PR cause a reduction of suscep-
tibility to the PR inhibitors nelfinavir, BMS-232632, and SC-
55389A (9, 23, 36). N88S/D mutations emerged in protease
sequences derived from 20% of individuals who had failed a
therapy regimen containing nelfinavir, though the two muta-
tions occured in different sequence contexts (23). A subset of
virus strains with reduced susceptibility to nelfinavir was sub-
sequently shown to have a 3- to 12-fold increase in suscepti-
bility to amprenavir, another PR inhibitor (40). The amprena-
vir hypersusceptibility was most strongly linked to the N88S
mutation, which by itself resulted in a 25-fold increase in am-
prenavir susceptibility. L63P led to a decrease of amprenavir
hypersusceptibility to 10-fold, and mutations M46L, L63P, and
V77I together led to an augmentation of the nelfinavir resis-
tance associated with N88S (Table 1) (40). The fitness of vari-
ants carrying the N88S mutation has been reported to be re-
duced compared to that of the wild type, as measured by
growth kinetics and replication capacity in a single cycle (36,
37, 40).
In an extension of previous observations, we employed four
experimental approaches to quantify the reduction of fitness
(parallel growth kinetics and virus cocultures) or components
of fitness (single-cycle replication capacity and specific infec-
tivity) associated with the mutation N88S in pro and the ability
of mutations M46L, L63P, and V77I, which can be found in
association with N88S in vivo, to compensate for the fitness
loss induced by N88S. This work not only extends previous
observations but also provides a systematic comparison of re-
sults obtained from commonly used assays of relative fitness
with assays that measure components of relative fitness, such
as infectivity and replication capacity. Finally, we demonstrate
that Gag processing is aberrant in strains carrying the N88S
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mutation and is partially restored with additional mutations,
although not with M46L.
MATERIALS AND METHODS
Construction of recombinant viral genomes. The construction of full-length
recombinant genomes and retroviral vectors was described previously (40).
Single-cycle replication capacity assay. Single-cycle replication capacity was
measured using a replication-incompetent HIV type 1 (HIV-1) vector in which
a luciferase gene was inserted into a deleted portion of the env gene as described
previously (25). Briefly, human embryonic kidney cell 293 cultures were cotrans-
fected by calcium phosphate precipitation with the HIV-1 luciferase vector
encoding the PR sequences of interest and either an amphotropic murine leu-
kemia virus (MLV) env gene or an HIV-1 env-expressing DNA construct. Trans-
fection efficiency, determined by luciferase expression in the transfected cells,
displayed less than 10% variability between samples transfected on the same day.
Virus particles were harvested 48 h after transfection and were used to infect
target 293 cells. Luciferase activity in target cells infected with mutant strains was
measured 48 to 72 h after infection and was normalized to luciferase activity
expressed by cells infected with the parental strain to give relative light units or
single-cycle replication capacity.
Virus stocks. For transfection, 293 cells were seeded at 4  105 cells/well in
six-well plates. One day after seeding, the cultures were transfected with 0.8 g
of plasmid DNA using Effectene reagents (Qiagen) according to the manufac-
turer’s instructions. Virus supernatants were collected 48 h after transfection,
clarified by centrifugation for 1 min at 3,000  g, and stored in aliquots at 80°C.
To generate virus stocks for coculture experiments, virus from the transfection
supernatants was passaged once through CEMx174 cells (AIDS Research and
Reference Reagent Program, National Institutes of Health) to remove residual
plasmid DNA. Sequences of the PR-coding domain and the CA/p2, p2/NC,
NC/p1, and p1/p6 processing sites were verified after this passage by sequencing
reverse transcriptase (RT)-PCR products.
RT activity assay. To quantitate virus growth, the activity of RT in the culture
supernatant was measured as described earlier (2), with the following modifica-
tions. The radionucleotide incorporated into the nascent DNA strand was 33P, a
vacuum manifold (Bio-Rad) was used to capture the newly synthesized DNA on
anion-exchange paper, and storage phosphor autoradiography (Storm 840 Phos-
phorImager; Molecular Devices) was used to quantitate incorporated radioac-
tivity.
Quantitative determination of capsid protein. The amount of capsid protein
(p24) in transfection supernatants was measured with an enzyme-linked immu-
nosorbent assay using a commercially available set of reagents (New England
Nuclear) according to the manufacturer’s instructions.
Specific infectivity assay. Virus stocks were generated by transfection of plas-
mid DNA harboring full-length HIV proviral genomes in triplicate as described
above. For each transfection supernatant, RT activity and the amount of capsid
protein were measured as described above. Virus titers in each transfection
supernatant were determined with the multinuclear activation of a galactosidase
indicator (MAGI) assay (14). Specific infectivity was calculated as the number of
infectious units per nanogram of capsid protein and was normalized to the
parental strain. Three to six transfection supernatants were used to calculate the
mean and standard deviation of specific infectivity.
Virus growth kinetics in parallel cultures. Aliquots of 6.3  104 infectious
units (IU) of virus, as determined by the MAGI assay, were allowed to adsorb to
3  106 CEMx174 cells for 2 h at 37°C in a volume of 0.5 ml. Unbound virus was
removed by two washes with phosphate-buffered saline, and cultures were main-
tained in 10 ml of RPMI 1640 medium supplemented with 10% fetal bovine
serum and antibiotics. Cells were transferred to fresh medium daily, and virus
growth was measured by determining the amount of RT activity in the culture
supernatants as described above and by calculating a dimensionless ratio of the
amount of radioactivity incorporated into DNA by RT activity present in the
culture supernatants at time t divided by the amount of radioactivity incorpo-
rated by the RT activity present in the supernatant of the same culture at the
peak of virus production (RT/RTmax).
The exponential growth model
RTt
RTmax

RT0
RTmax
 ert
RT0
RTmax
 eqt (1)
was fit to the data to obtain an estimate of the net exponential growth constant
q (1/day). Note that q is a net rate constant that includes the rate of new
infections (r) and the rate of death of productively infected cells ().
Virus cocultures. H9 cells (AIDS Research and Reference Reagent Program,
National Institutes of Health) were maintained in RPMI 1640 medium supple-
mented with 10% fetal bovine serum and antibiotics. Cultures were started with
3  106 H9 cells and 1,000 to 5,000 total IU as determined by the MAGI cell
assay in a total volume of 0.5 ml. After 2 h, excess virus was removed by two
washes with phosphate-buffered saline and the cultures were maintained as
described in the previous section. The less fit virus strain was introduced into the
culture at a 2- to 10-fold excess of IU over the fitter strain. RT activity in the
culture supernatant was measured to monitor the extent of virus replication, and
the ratio of the two strains was determined daily from viral RNA in the culture
supernatant using RT-PCR and a heteroduplex tracking assay (HTA) (31).
Briefly, viral RNA was extracted from culture supernatants using the QIAmp
viral RNA kit (Qiagen), RT-PCR products spanning codons 18 to 99 of pro were
generated and annealed to a radioactively labeled DNA probe, and the resulting
DNA heteroduplexes were resolved by native polyacrylamide gel electrophoresis.
The heteroduplex bands corresponding to the two virus strains in the culture
were quantitated by storage phosphor autoradiography to determine the relative
abundance of the two virus strains. Two different probes were used to resolve the
different virus strain combinations. To resolve the mixture of parental strain with
the strain containing only the N88S substitution, probe 16.12EB was used. This
is a site-specific probe derived from probe 6.1 described previously (31). All
other combinations of virus strains were resolved using probe 5.5/1 derived from
an HIV-1 clade A virus isolate. This isolate differs from clade B consensus in 6%
of the nucleotide positions of the probe, which allows the nonspecific detection
of multiple mutations. These procedures are similar to previously published
applications of cocultures (12, 21, 28, 30).
Computation of relative fitness from cocultures and parallel cultures. The
fitness difference of two continuously replicating organisms is defined as the
difference of their replication rate constants and is dependent on the absolute
replication rates realized in the experimental setup. However, the fractional
difference s (selection coefficient) between the replication rates is not dependent
on the absolute rates. It is defined as
rM 1 srW (2)
s
rM rW
rW
where rM and rW are replication rates of a mutant and wild-type strain, respec-
tively, and 1  s is the relative fitness or difference (n-fold) between the growth
constants. One can calculate an apparent selection coefficient, sapp, from the net
replication rates obtained from single virus cultures using equation 2
sapp
qM qW
qW
(3)
For the relationship between sapp and s, we find
sapp s 
rW
rW 
(4)
In the text we estimate the magnitude of the error associated with using the net
replication rates as opposed to the real replication rates from equation 4. The use
of net replication rates results in an overestimate of the absolute value of s.
The most general model for the determination of the selection coefficient from
coculture experiments has been proposed by Mare´e and coworkers (19). In this
model, without requiring that growth rates be constant over the course of the
experiment, the selection coefficient s can be computed as
TABLE 1. Relative susceptibility of HIV-1 protease mutants to
nelfinavir (NFV) and amprenavir (AMP)a
Virus strain
Relative susceptibility to:
NFV AMP
NL4-3 (W) 1.00 1.00
N88S (S) 2.40 0.04
L63P/V77I/N88S (T) 12.90 0.08
M46L/L63P/V77I/N88S (Q) 12.20 0.14
a Data taken from reference 40.
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s
ln
Ht
H0
ln
Wt
W0 t
(5)
where W(t)/W(0) is the ratio of wild-type virus at time t and time 0 or the
expansion (n-fold) of the wild-type virus, H(t)/H(0) is the change (n-fold) of the
mutant-to-wild- type ratio H  M/W, and  is the rate of decay of productively
infected cells (1/ is the average life span of an infected cell). This equation was
rewritten as
ln
Ht
H0 sln WtW0 t (6)
so that s could be determined as the slope of the best-fit line obtained by linear
regression of ln
Ht
H0 versus ln
Wt
W0  t . The expansion (n-fold) of the wild-type
strain in coculture experiments was calculated from the increase (n-fold) of RT
activity in the culture supernatant, and the abundance of the wild-type strain was
determined using HTA. The ratio of the two viruses was determined by HTA.
The average life span of infected cells is unknown for the in vitro culture
conditions employed here. This problem can be approached in two ways. First, 
can be ignored (  0), and sapp can be calculated. Again, this leads to an
overestimate of the absolute value of s. The relationship between sapp and s was
derived from equation 5
sapp s1 
t
lnWtW0 (7)
An estimate of the difference (n-fold) between sapp and s is given in the text. The
mean of the constant t/ln[W(t)/W(0)], which was determined experimentally and
used in the estimate, was 0.7 day (99% confidence interval, 0.6 to 0.8).
The model proposed by Mare´e et al. can be rewritten into the model proposed
by Holland and coworkers (12) if it is assumed that the replication rate does not
change over the course of the experiment. The assumption of a constant repli-
cation rate is valid in the exponential phase of virus growth. This model predicts
that the logarithm of the mutant-to-wild-type ratio changes linearly with time t
(equation 8, which follows below) and that the slope p of that line, where p rWs,
represents the difference of the replication rate constants of the two viruses.
ln
Mt
Wt
 pt ln
M0
W0 (8)
Equation 8 can be used to calculate the change (n-fold) of the mutant-to-wild-
type ratio per time period d (	d) in the coculture as
	d erW sd (9)
The terminology of wild-type and mutant strains is arbitrary and is used here
for simplicity only. The same models apply to any combination of strains.
Analysis of Gag processing. A 500-l aliquot of transfection supernatant
containing HIV-1 virions was centrifuged at 21,000  g for 1.5 h in a microfuge.
Pellets containing virus particles were resuspended and lysed in 50 l of sample
buffer (0.45 M Tris HCl, pH 8.45, 12% [vol/vol] glycerol, 4% [wt/vol] sodium
dodecyl sulfate [SDS], 50 mM dithiothreitol, 0.0075% Coomassie blue G, and
0.0025% phenol red). Approximately equal amounts of lysed virus particles as
determined by the amount of RT activity in the transfection supernatant were
subjected to denaturing tricine-SDS-polyacrylamide gel electrophoresis as de-
scribed previously (33). Proteins were transferred to a polyvinylidene difluoride
membrane, and viral proteins were detected with either monoclonal mouse
anti-p24 (Cellular Products) or polyclonal rabbit anti-p15 (provided by S. Erick-
son-Viitanen) antibodies using enhanced chemiluminescence (ECLplus; Amer-
sham). ECLplus allows the detection of luminescence as well as blue-excited
fluorescence (Storm 840 PhosphorImager; Molecular Devices) for quantitation.
This anti-p15 antibody appears to be largely specific for NC and NC-p1, as its
reactivity in Western analysis is identical to that of an anti-NC monoclonal
antibody (data not shown).
RESULTS
The N88S mutation in PR reduces specific infectivity and
single-cycle replication capacity. The N88S mutation in PR has
been observed during failure of antiretroviral treatments con-
taining nelfinavir (23, 40). In some viruses, N88S was associ-
ated with mutations at PR positions 46, 63, and 77, and these
mutations were found to augment the reduction of nelfinavir
sensitivity associated with N88S (Table 1) and partly relieve
defects in single-cycle replication capacity induced by the N88S
substitution (40). We examined specific infectivity and single-
cycle replication capacity of four virus strains—N88S (single
mutant, S), L63P/V77I/N88S (triple mutant, T), and M46L/
L63P/V77I/N88S (quadruple mutant, Q)—compared to the
parental NL4-3 strain (wild type, W) and compared the ob-
served impairment of these measures with the reduction of
fitness determined in virus cocultures and parallel growth ki-
netics experiments (see subsequent sections).
Specific infectivity or average per-particle infectivity was
measured as the number of IU (MAGI assay) per nanogram of
capsid protein of a mutant relative to the parental strain in
transfection supernatants generated from plasmid DNA (Fig.
1). The specific infectivity of the three mutant strains was
reduced to 46% 
 7% (S; mean and standard deviation), 50%

 21% (T), and 24% 
 5% (Q) relative to W. Strain Q
appeared to be less infectious than S, while T was indistin-
guishable from S. We also noted that, in strain Q (adding a
M46L mutation), the ratio of RT activity to capsid protein in
the transfection supernatants was reduced to 68% of that
found in the wild type (data not shown).
The effect of the mutations in PR on single-cycle replication
capacity was determined using an HIV-1-based resistance-test-
ing vector encoding a luciferase gene (25). Pseudotyped virus
particles were generated with two different Env proteins to
exclude the possibility of entry phenomena confounding mea-
surements of PR mutants. Single-cycle replication capacity of
virus strain S was reduced to 1% 
 1% (n  12) and 3% 
 1%
(n 3) compared to that of the wild type, using MLV and HIV
env, respectively (Fig. 1). This phenotype was partially rescued
by the addition of mutations L63P and V77I in strain T, raising
single-cycle replication capacity to 31% 
 8% (n  12; MLV
env) and 43% 
 12% (n  3; HIV env). The addition of M46L
FIG. 1. Single-cycle replication capacity (RC) and specific infectiv-
ity (Spec. Inf.) of HIV-1 strains carrying N88S mutations in PR relative
to the parental strain (W). Single-cycle replication capacity was mea-
sured using a retrovirus vector pseudotyped with MLV amphotropic
Env protein or HIV Env protein. Specific infectivity was measured as
the number of IU per nanogram of p24 capsid protein relative to the
parental strain using infectious molecular clones. Note that all single-
cycle-based assays showed similar results for two strains (T and Q) and
that strain S showed a marked difference between the single-cycle
replication capacity and specific infectivity assays. Error bars represent
standard deviations. S, N88S; T, L63P/V77I/N88S; and Q, M46L/L63P/
V77I/N88S.
VOL. 76, 2002 MUTATION N88S IN HIV-1 PROTEASE REDUCES VIRAL FITNESS 8661
resulted in an intermediate phenotype between the S and T
mutants (15% 
 10%, MLV env, n  6; 10% 
 4%, HIV env,
n  3), indicating that M46L does not act as a compensatory
mutation in this assay. These results are consistent with the
specific infectivity for strains T and Q, but the impairment of
strain S was significantly greater in the replication capacity
assay than in the specific infectivity assay. There was no statis-
tically significant difference between measurements carried out
with the different Env proteins.
Strains S and Q have reduced replication kinetics compared
to the parental strain in parallel cultures. The kinetics of the
accumulation of RT activity in CEMx174 cells was measured to
estimate the replicative disadvantage associated with the N88S
mutation alone or in combination with substitutions at posi-
tions 46, 63, and 77 during multiple rounds of replication (Fig.
2). Qualitatively, it appeared that strains W and T grew at
comparable rates, whereas strains S and Q spread at lower
rates. An exponential growth model was fit to the data from
each culture to estimate the net growth rate constant q. This
suggested that the four virus strains in order of fitness were W
(q  2.9 
 0.02 day1), T (q  2.7 
 0.1 day1), S (q  2.2 

0.1 day1), and Q (q 2.0
 0.1 day1), though the differences
between W and T and those between S and Q were small.
Growth constants are given as a mean and 1 standard devia-
tion.
The fractional difference of mutant and wild-type net growth
constants was used to estimate the fitness of the mutant strains
relative to that of the wild type (see equations 2 and 3) as 76 

3% (S), 92 
 5% (T), and 68 
 2% (Q) (summarized in Fig.
4). Equation 4 (Materials and Methods) was used to estimate
the error associated with using net growth constants in the
calculation of relative fitness. For this estimate we used previ-
ously published values for the decay rate constant of infected
cells in vivo of approximately 0.5 day1 (10, 24, 29, 38). Under
these conditions, the absolute value of the apparent selection
coefficient is a 1.2- to 1.3-fold overestimate of the true value of
s, i.e., the relative fitness would be underestimated. The decay
rate constant may be lower in vitro than in vivo, due to the
absence of cytotoxic T cells, consistent with a report of a
somewhat longer life span of infected cells observed in trans-
formed T cells (8). A lower decay rate (longer life span) would
reduce the magnitude of the error.
Strains S, T, and Q display reduced fitness relative to that
of the parental strain in virus cocultures. To confirm the
validity of the growth kinetics results, internally controlled
virus cocultures were carried out in H9 cells. Virus coculture
experiments, also termed growth competition cultures, were
started at a summed multiplicity of infection of between 0.0003
and 0.002 for pairs of viruses. The cocultures were carried out
with mixtures of two strains at different initial ratios with the
less fit virus usually being in excess. The total amount of virus
over the course of the experiment was measured using an RT
assay for supernatant virus, and the ratio of the two strains in
each culture was determined daily from supernatant viral RNA
using RT-PCR and an HTA. The abundance of the two bands
detected by HTA reflects the relative abundance of the two
virus strains in the culture. Cultures representative of the three
to six cultures carried out for each combination of two strains
are shown in Fig. 3A to E. These results suggested that all
three mutant strains had impaired replication capacity com-
pared to that of the parental strain, that S and T were compa-
rable in replication capacity, and that Q was marginally less fit
than S.
To determine a selection coefficient analogous to the previ-
ous section, we used a modification of a model proposed by
Mare´e and coworkers (19) (see equation 6 in Materials and
Methods). Using this model, s can be determined by linear
regression. Since the decay rate of productively infected cells,
, is not known precisely for our experimental conditions, we
decided to calculate an apparent selection coefficient by ignor-
ing the t term. As in the previous section, we caution that sapp
represents a 1.3- to 1.4-fold overestimate of s (underestimate
of relative fitness) as computed from equation 7 (Materials and
Methods), assuming that the average life span of infected cells
is similar to that published previously for cells in vivo.
Figure 3F shows an example of the analysis of the coculture
data using this model. The slope of the regression line equals
sapp. Model fit was similar to that for the example shown in Fig.
3F for all competitions. When the results from multiple inde-
pendent coculture experiments were analyzed, no significant
differences of relative fitness were found between the three
mutants in competition with the wild type, although the trend
of W(100%)  T(83% 
 8%)  Q(79% 
 6%)  S(72% 

8%) is suggested (Fig. 4). In direct competition, however, Q
was consistently less fit than S, whereas S and T had similar
fitness.
Polyprotein precursor processing is aberrant in viral strains
carrying the N88S mutation. Processing of the polyprotein
precursor Gag by the virally encoded PR is a required step in
the formation of infectious virus particles, and processing de-
fects are associated with reduced infectivity (39). To test if
aberrant processing of Gag correlated with the observed defi-
ciencies in infectivity, Gag processing was examined in virus
particles generated after transfection of the infectious molec-
ular clones of NL4-3 carrying the four different pro genes (Fig.
5). Compared to what was found for the wild type, a higher
proportion of partially processed Gag intermediates was de-
tected with both antibodies in the S strain. While the p24
capsid processing appeared to be wild-type-like in the T and Q
FIG. 2. Replication kinetics of HIV-1 strains carrying N88S muta-
tions in PR. The three mutant strains and the parental strain were
inoculated into three (W and T) or four (S and Q) independent
cultures, and the rate of virus spread through the culture was followed
by measuring the amount of RT activity in the culture supernatant. RT
activities were normalized to the peak RT level (RTmax)and averaged.
Error bars represent standard deviations. W, parental strain (NL4-3);
S, N88S; T, L63P/V77I/N88S; and Q, M46L/L63P/V77I/N88S. dpi,
days postinfection.
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strains, NC processing was only partially restored in these
strains. Particularly pronounced in all three mutant strains is
an apparent reduction in the efficiency of the NC-p1 site cleav-
age, as indicated by the detection of a protein with an apparent
molecular mass of 8 kDa. The presence of the putative NC-p1
protein correlated better with reduced infectivity and fitness
than did the presence of partially processed, capsid-containing
Gag fragments.
DISCUSSION
The goals of this study were threefold. First, we attempted to
extend previous observations of reduced replication capacity of
nelfinavir-resistant and amprenavir-hypersusceptible HIV-1
strains harboring an N88S mutation and to test the ability of
second-site mutations in PR to rescue the reduction of fitness.
Second, we carried out various well-established measurements
used to determine relative fitness of virus strains in a effort to
compare qualitative and quantitative outcomes of these assays.
Third, we investigated the correlation of measures of fitness
with aberrant processing of the Gag polyprotein precursor.
FIG. 3. Representative virus coculture experiments. Cultures were inoculated with mixtures of two virus strains at a low multiplicity of infection,
and the rate of change of the ratio of the two strains was measured over time. For each combination of strains tested, the abundance of either strain
over time as well as the HTA gel used to measure the abundances is shown for one representative experiment. (A) S versus W; (B) T versus W;
(C) Q versus W; (D) T versus S; and (E) Q versus S. (F) Analysis of the results of an S-versus-W competition culture using a model proposed by
Maree´ and coworkers (19). The slope of the line represents s, the fractional difference of the fitness of strain S relative to strain W. W, parental
strain (NL4-3); S, N88S; T, L63P/V77I/N88S; Q, M46L/L63P/V77I/N88S; dsP, double-stranded probe; dpi, days postinfection; H, M/W; WT, wild
type.
FIG. 4. Relative fitness (1  s) measured by cocultures and parallel
cultures. Relative fitness measured by cocultures (white bars; S versus
W, n  3; T versus W, n  6; Q versus W, n  5; T versus S, n  3;
Q versus S, n  3) and parallel cultures is shown. Error bars represent
standard deviations. Note that the results are comparable except for
the smaller fitness reduction of strain T suggested by the parallel
cultures. s, selection coefficient or fractional fitness difference; 1 sapp,
relative fitness; W, parental strain (NL4-3); S, N88S; T, L63P/V77I/
N88S; and Q, M46L/L63P/V77I/N88S.
VOL. 76, 2002 MUTATION N88S IN HIV-1 PROTEASE REDUCES VIRAL FITNESS 8663
In all four assays (specific infectivity, single-cycle replication
capacity, parallel cultures, and virus cocultures), strain T
(L63P/V77I/N88S) performed consistently better than strains S
(N88S) and Q (M46L/L63P/V77I/N88S) but did worse than the
parental wild-type strain, though the differences were not sig-
nificant in all assays. This suggests that the mutations L63P and
V77I, in combination, partially compensate for the loss of
fitness caused by N88S, while at the same time increasing
nelfinavir resistance from 2- to 13-fold and decreasing am-
prenavir hypersusceptibility from 25- to 13-fold. We hypothe-
size that the hypersusceptibility of strain S to amprenavir is at
least partially a result of reduced fitness due to a decrease of
total PR activity in the virion. This is consistent with improved
processing of the NC-p1 PR cleavage site in strain T compared
to strain S and with the previous observation of a general
increase in catalytic efficiency of PR mediated by the L63P
mutation (34). In addition, L63P has been reported to be a
compensatory mutation for L90M (21). The correlation of the
incomplete cleavage of the NC-p1 site with reduction of fitness
is in agreement with the high frequency of substitutions at this
site in PR inhibitor-resistant strains (4). However, increased
amprenavir binding affinity of the mutant PRs cannot be ex-
cluded as a possible explanation for hypersusceptibility (40).
The addition of the M46L mutation to strain T to yield strain
Q resulted in a decrease of fitness and infectivity in all assays
without changing the pattern of processing at the NC-p1 site or
further increasing nelfinavir resistance. However, the hyper-
susceptibility to amprenavir was reduced to sevenfold, while
the ratio of RT activity to capsid protein fell to 68% of the
ratio observed in the parental strain. The reduction of the
RT-activity-to-p24-protein ratio is consistent with the previ-
ously reported reduction of virion-associated RT activity for
other PR inhibitor-resistant strains (6). These observations
suggest that the M46L mutation had a modest effect on am-
prenavir sensitivity and may have resulted in reduced virion
incorporation of the RT-containing Gag-Pro-Pol precursor
protein.
Strain Q, in direct competition, was less fit than strain S
and had a lower specific infectivity and slower replication
kinetics in parallel cultures and thus is the most impaired
mutant in this study. The reduction in fitness associated with
the inclusion of the M46L mutation did not correlate with a
reduction of the NC-p1 cleavage efficiency (Fig. 3), suggest-
ing a distinct mechanism of fitness loss for this mutation.
Surprisingly, the single-cycle replication capacity measured
for strain S was considerably lower (5% of wild type) than
expected, given the results of all other assays. One possible
explanation for this difference may have been a reduced
stability of strain S that could have led to different estimates
of fitness reduction depending on the storage and treatment
conditions during the experiment. However, in a preliminary
analysis, we found no evidence for reduced stability of strain
S compared to that of the other strains (data not shown).
Alternatively, technical differences between the experi-
ments, such as the use of different cell lines for infection,
could account for the observed differences in infectivity. A
difference between replication capacity and specific infec-
tivity has been observed with several other mutant PRs
(unpublished observation), indicating that this phenomenon
is not restricted to the N88S class mutants. The magnitude
of reduction of specific infectivity reported here for the
N88S-carrying strain was similar to the reduction of PR
catalytic efficiency to 20 to 40% of that found in the wild
type, observed for a different mutation at position 88 linked
to nelfinavir resistance (N88D) (17), and the relative fitness
measurements were comparable to the 80% relative fitness
observed in vivo for virus strains harboring the N88D sub-
stitution (7).
In order to compare the reduction of specific infectivity and
single-cycle replication capacity to the reduction of fitness
measured in cocultures during multiple rounds of infection, we
reasoned that the fold change of the mutant-to-wild-type ratio
in the virus cocultures per generation should be comparable to
the single-cycle replication capacity and specific infectivity, if
the reduction of infectivity alone is sufficient to explain the loss
of fitness. The fold change of the mutant-to-wild-type ratio
per generation can be calculated as 	  erWs, where  is the
generation time in days and rW the replication rate of the wild
type. From our virus coculture experiments, we estimated rW to
be 2 days1 (95% confidence interval, 1.8 to 2.2), assuming
that the turnover rate of infected cells was approximately 0.5
day1 and that the generation time  was approximately 2 days,
as has been determined previously by in vivo and in vitro
experiments (8, 10, 24, 29, 38). Table 2 compares the results
from single-cycle assays with relative fitness and 	. We found
that the change of specific infectivity is sufficiently close to the
change (n-fold) of the mutant-to-wild-type ratio in the compe-
tition cultures to conclude that the reduction of specific infec-
tivity is the main cause for the reduction of viral fitness. In the
set of virus strains discussed here, the correlation between the
two approaches was sufficient to suggest the use of the signif-
icantly faster and more reproducible single-cycle-based assays
as a surrogate for fitness during multiple cycles of infection for
mutants in which the reduction of fitness is largely caused by a
FIG. 5. Processing of Gag polyprotein precursor. Virus particles of
the HIV-1 strains W, S, T, and Q were analyzed by SDS-polyacryl-
amide gel electrophoresis and Western blotting using anti-p15 and
anti-p24 antibodies. Only the relevant parts of the gels are shown here.
Incomplete processing of nucleocapsid (NC)- and capsid (C)-contain-
ing fragments was apparent in strain S. The addition of the L63P and
V77I mutations in strains T and Q resulted in a compensation of the
capsid-processing defect, whereas there was only a partial recovery of
the nucleocapsid-processing defect in strains T and Q. W, parental
strain (NL4-3); S, N88S; T, L63P/V77I/N88S; Q, M46L/L63P/V77I/
N88S; and MA, matrix. All lanes contained viral proteins from the
comparable numbers of virions.
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reduction of specific infectivity or replication capacity. Similar
concordance of single-cycle assays and virus culture assays has
been observed by others (27). However, this correlation will
need to be extended to other classes of PR mutants to under-
stand more fully the differences between the single-cycle rep-
lication capacity assay and the specific infectivity assay and the
impact of different mechanism of fitness loss and compensa-
tion on these assays. This is especially important in the light of
the discordance between one of the single-cycle assays and all
other assays for one of the mutant strains.
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